ALLMedicine™ Myelodysplastic Syndromes Center

Jun 25th, 2022 - Splicing factor 3B subunit 1 (SF3B1) somatic mutation in the context of therapy-related myelodysplastic syndromes (t-MDS) has not been well defined. In a large cohort of patients with MDS, those with known SF3B1 somatic mutation were compared as d...

Jun 24th, 2022 - BACKGROUND: The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models, justifying the clinical evaluation of this combinatio...

Jun 24th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Jun 24th, 2022 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...

Jun 24th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

Jun 24th, 2022 - Background: Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies. The aim of this protocol is to facilitate biologic study of leukemia...

Jun 24th, 2022 - BACKGROUND: The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models, justifying the clinical evaluation of this combinatio...

Jun 24th, 2022 - The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in p...

Jun 24th, 2022 - The drug being tested in this study is called Pevonedistat. Pevonedistat is being tested to treat people with myelodysplastic syndromes MDS (including nonproliferative chronic myelomonocytic leukemia [CMML]) and AML (acute myeloid leukaemia) as a ...

Jun 24th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Apr 22nd, 2022 - Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Approximately half the patients diagnosed with MD...

Apr 15th, 2022 - Treatment with a treosulfan-based conditioning regimen led to a superior event-free and overall survival (OS) compared with busulfan-based conditioning in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transpla...

Mar 1st, 2022 - The first decision in newly diagnosed, advanced ovarian cancer is whether to pursue primary debulking or neoadjuvant chemotherapy, determined in part by the presence of pleural effusion, significant ascites, and diffusely metastatic disease. Howev...

Feb 28th, 2022 - The FDA has granted an orphan drug designation to eltanexor (KPT-8602), an investigational novel SINE compound, as a potential therapeutic option for patients with myelodysplastic syndromes (MDS), according to an announcement from Karyopharm Thera...

Feb 28th, 2022 - The combination of oral decitabine and cedazuridine (Inqovi) was well tolerated and provided potentially promising outcomes in patients with lower-risk myelodysplastic syndromes (MDS), according to results from the phase 3 ASCERTAIN trial (NCT0330...